 Home > Biochemical Engineering > Chinese Herbs > Eloralintide for Sale > Eloralintide2883634-40-8

Eloralintide2883634-40-8 buy - large image1

Eloralintide2883634-40-8

Name: Eloralintide2883634-40-8
Brand: OORENT
SKU: pr2610211735
Price: 33 USD
Availability: InStock

82 Inquiries

Unit Price:

$33-34/MT FOB

Get Latest Price 

CAS No.:

2883634-40-8

Grade:

Pharmaceutical Grade

Content:

99.5%

Port:

shanghai

Brand:

OORENT

Packaging:

Vial/Bottle/Bag/Carton

Sample Available:

Yes

Price valid (until):

2026-11-21

Contact Supplier

 Chat Now

Qingdao Orient Chemical Co.,LTD

Company Type:

Trader

Location:

China

Payment Terms:

100% TT in advance

Average Lead Time:

10 days

Qualification:

Main Products:

pharmaceutical intermediates,peptides,electronic chemicals

 Visit Store

Product Details
Seller Information
Inquiry History

Description

Product Detailv

Retatrutide Basic information

Product Name:	Retatrutide
Synonyms:	LY3437943;Retatrutide;GIPR/GLP-1R;Retatrutide/LY3437943/GIPR/GLP-1R;Retaglutide;Retatrutide acetate;LY3437943Retatrutide;Retalutide
CAS:	2381089-83-2
MF:
MW:	0
EINECS:	200-001-8
Product Categories:
Mol File:	Mol File

Retatrutide Chemical Properties

storage temp.	-20°C
solubility	Acetonitrile: Slightly soluble DMSO: Sparingly Soluble: 1-10mg/mLPBS (pH 7.2): Sparingly Soluble: 1-10mg/mL Water: Slightly soluble
form	powder
color	White lyophilized
Water Solubility	Soluble in water (5mg/ml).

Safety Information

MSDS Information

Retatrutide Usage And Synthesis

Description	Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research. Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
History	Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.
Biological Activity	Retatrutide (LY3437943), a single peptide conjugated to a lipid diacid molecule, exerts a powerful agonist effect on the human glucagon‐receptor (GCGR), GIPR, and GLP‐1R. In comparison with the human glucagon and glucagon‐like peptide 1 (GLP‐1), retatrutide exhibits reduced potency (by a factor of 0.3 and 0.4, respectively) on the GCGR and GLP‐1R while displaying enhanced potency at the human GIPR (by a factor of 8.9) when compared to the glucose‐dependent insulinotropic polypeptide (GIP)[7].
Mechanism of action	When injected into mice suffering from diabetes-induced kidney injury, retatrutide was found to markedly reduce albuminuria levels while also increasing renal filtration rate. This was attributed to its ability to activate GLP-1R/GR-dependent signalling pathways, which then produced anti-inflammatory and antiapoptotic effects that protected the kidneys from further damage. Additionally, it has been shown to directly modulate glomerular permeability, thus leading to improved urinary concentration. Initial results indicate that the peptide can induce marked improvements in albuminuria levels within just four weeks of treatment when compared to other treatments for chronic kidney disease such as ACE inhibitors or angiotensin receptor blockers (ARBs). Moreover, retatrutide has demonstrated a greater effect than either ACE inhibitors or ARBs at reducing systolic blood pressure without inducing significant side effects.
Side effects	The most common side effects of retatrutide are gastrointestinal, including: Nausea, Diarrhea, Vomiting, and Constipation. At higher doses, researchers stated these symptoms were "mostly mild to moderate in severity" and typically treated by lowering the dosage. However, 7% of patients also experienced skin tingling. At 24 weeks of treatment, patients' heart rates on higher doses peaked but declined afterward.
in vitro	In vitro, Retatrutide demonstrates similar efficacy to natural glucagon in evoking glucose production within hepatocytes. Meanwhile, in adipocytes, it surpasses native GIP in inducing lipolysis. Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity. Retatrutide demonstrates dosage‐dependent pharmacokinetics, featuring a favourable half‐life of nearly 6 days, enabling convenient weekly administration. Additionally, GLP‐1 and GCG are known to significantly delay GE in humans, while GIP may have no impact on GE. Delayed GE reduces food consumption and, therefore, leads to weight reduction[7].
References	[1] LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: T. Coskun, et al.; Cell Metab. 34, 1234 (2022) DOI:10.1016/j.cmet.2022.07.013 [2] The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying: S. Urva, et al.; Diabetes Obes. Metab. 25, 2784 (2023) DOI:10.1111/dom.15167 [3] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial: S. Urva, et al.; Lancet 400, 1869 (2022) DOI:10.1016/S0140-6736(22)02033-5 [4] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity S.A. Doggrell; Expert Opin. Investig. Drugs 32, 355 (2023) DOI:10.1080/13543784.2023.2206560 [5] Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943: A. Regmi & W. Roell; STAR Protoc. 4, 102304 (2023) DOI:10.1016/j.xpro.2023.102304 [6] Gut hormone co-agonists for the treatment of obesity: from bench to bedside: R. Nogueiras, et al.; Nature Metab. 5, 933 (2023) (Review) DOI:10.1038/s42255-023-00812-z [7] Muhammad Naeem, Umm E Salma Shabbar Banatwala, Laiba Imran. “Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.” Health Science Reports 7 2 (2024).

Retatrutide Preparation Products And Raw materials

Shop Tirzepatide2023788-19-2-Detailed Image 2

Shop Tirzepatide2023788-19-2-Detailed Image 3

Shop Tirzepatide2023788-19-2-Detailed Image 4

Shop Tirzepatide2023788-19-2-Detailed Image 5

Shop Tirzepatide2023788-19-2-Detailed Image 6

Shop Tirzepatide2023788-19-2-Detailed Image 7

ECHEMI Editorial Reference

Eloralintide (CAS No. 2883634-40-8) is a long-acting amylin analog and peptide-based pharmaceutical ingredient. Its modified peptide structure features a methylene thioacetal bridge and a C20 fatty diacid side chain, contributing to its distinctive molecular and physicochemical properties. As a peptide pharmaceutical raw material, Eloralintide is suitable for API research, analytical studies, and pharmaceutical development.

Basic Info

Product Name:

Eloralintide

Other Name:

Eloralintide;AMY1176;LY3841136;Eloralintide,LY3841136

CAS No.:

2883634-40-8

Molecular Weight:

EC Number:

262-076-3

Color/Form:

White to off-white

Categories:

Chinese Herbs

Research

Class:

Amylin receptor (AMYR) agonist (peptide, long-acting)

Status:

Investigational — Phase 1/2 (T2DM and obesity)

Mechanism:

Eloralintide is an amylin receptor agonist developed by Eli Lilly for type 2 diabetes and obesity. It activates the amylin receptor (AMYR), reducing food intake, delaying gastric emptying, and promoting satiety. It is structurally distinct from cagrilintide (Novo Nordisk). Being explored as monotherapy and in combination with GLP-1R agonists.

Activity note:

Limited public data. Eloralintide is in early clinical development; specific EC50 values have not been publicly disclosed.

Source:

MCE: Eloralintide (CAS 2883634-40-8); AbMole product data sheet.

References

PubChem:

PubChem

Literature:

MCE: Eloralintide (CAS 2883634-40-8); AbMole: Eloralintide (LY 3841136)

Disclaimer:

Eloralintide is NOT FDA-approved or EMA-approved. It is in Phase 1/2 clinical development by Eli Lilly. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

Seller Information

Business Type:
Trader

Main Products:
pharmaceutical intermediates,peptides,electronic chemicals

Location:
Room 102, 1st Floor, East Office Building, No. 45 Pengwan Road, Qianwan Bonded Port Area, Qingdao Zone, China (Shandong) Pilot Free Trade Zone

Payment Terms:
100% TT in advance

Average lead Time:
10 days

Total Annual Revenue:
$10 million-$25 million

Total Employees:
51-100

Year of Establishment:
2024

A reliable supplier is like insurance.

We are mainly specilized in supply of pharmaceutical intermediates, electronic chemicals，food additives, and other fine chemical products.
Integrity is the foundation, quality is life. We would like to work together with you to build a greener and brighter future.

Website: orientchem.cc
Email: scarlett@orientchem.cc
WhatsApp: +86 17753254221

Inquiry History

82 Inquiries

Country	Product	Purchase Quantity	Date Posted
United States	Eloralintide	1 KG	May 28, 2026
Australia	ELORALINTIDE	10 PCS	Oct 2, 2026
United Kingdom	Eloralitide	2 G	Sep 27, 2026
United Kingdom	Eloralintide	30 MG	Sep 22, 2026
United States	Eloralintids	10 MG	Sep 18, 2026
United States	Eloralintide	10 MG	Sep 13, 2026
United Kingdom	Eloralintide	1 G	Sep 1, 2026
United States	Eloralintide	1 MT	Aug 31, 2026
United States	Eloralintide	1 G	Aug 27, 2026
Italy	Eloralintide	5 PCS	Aug 19, 2026
United States	eloralintide	2 PCS	Aug 2, 2026
United States	eloralintide	30 MG	Jul 28, 2026
United States	Elora	32 G	Jul 27, 2026
United States	Eloralintide	1 G	Jul 13, 2026
United States	Eloralintide	10 PCS	Jul 11, 2026
Singapore	Eloralintide	1 G	Jul 1, 2026
United States	eloralintide	50 MT	Jun 12, 2026
United States	Eloralintide and Retatrutide	2 MT	Jun 8, 2026
United States	Eloralintide	5 PCS	May 27, 2026
South Korea	eloralintide	2 G	Feb 24, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Eloralintide LY3841136 CAS 2883634-40-8 Bulk Peptide Raw Material, Factory Supply	Pharmaceutical Grade/99.8	$20-23/G FOB	Shanxi Xinghengyuan Technology and Trade Co., Ltd.	Inquiry
Eloralintide CAS.2883634-40-8	Pharmaceutical Grade/99	$5-6/MT FOB	Hainan Flying International Trade Co., L	Inquiry
Eloralintide 5mg New Products Factory Wholesale Price High Quality Lyophilized	Pharmaceutical Grade/99	$55/MT FOB	Chongqing Chenmingheng Trading Co., Ltd.	Inquiry
Eloralintide 10mg 20mg New Products Factory Wholesale Price High Quality Lyophilized Powder Peptide new	Pharmaceutical Grade/99	$30/G FOB	Guangzhou Changkai Trading Co., Ltd.	Inquiry
Custom Peptides Pure 98% LY3841136 AMY1176 Raw Powder Eloralintide CAS 2883634-40-8	Research Grade/99	$20.4-25.5/G FOB	Tianjin Huifeng Technology Co., Ltd.	Inquiry

Eloralintide2883634-40-8

Product Details

Seller Information

Inquiry History

More Choices Find All Products for Sale 

Related Searches

More from this Seller